Oxcarbazepine is NOT recommended for mood swings
Oxcarbazepine lacks FDA approval for mood disorders and has insufficient evidence to support its use for mood swings. The FDA has only approved oxcarbazepine for partial-onset seizures in epilepsy 1. While it is structurally related to carbamazepine (which has some evidence in bipolar disorder), oxcarbazepine itself has not demonstrated reliable efficacy for mood stabilization.
Evidence Quality and Limitations
The available evidence for oxcarbazepine in mood disorders is weak:
No placebo-controlled efficacy in mania: A Cochrane systematic review found no difference between oxcarbazepine and placebo for the primary outcome (≥50% reduction in mania symptoms) in the only available placebo-controlled trial, which was conducted in children 2. No adult placebo-controlled studies exist.
No superiority over established mood stabilizers: When compared to valproate, oxcarbazepine showed no difference in antimanic efficacy 2. The evidence comparing it to lithium is essentially absent.
Limited and low-quality data: The systematic review identified only 7 studies with 368 participants total, all with "relatively low" methodological quality 2. These studies focused on mania, hypomania, mixed episodes, or rapid cycling—not general "mood swings."
What the Guidelines Actually Recommend
The American Academy of Child and Adolescent Psychiatry guidelines for bipolar disorder explicitly state that treatment should begin with FDA-approved agents 3. The recommended first-line options are:
- Lithium (approved for ages 12+ for acute mania and maintenance)
- Valproate, aripiprazole, olanzapine, risperidone, quetiapine, or ziprasidone for acute mania in adults
Notably, oxcarbazepine is not mentioned as a recommended agent in these guidelines 3. The guidelines note that carbamazepine (oxcarbazepine's parent compound) has "some support" in adult studies, but even carbamazepine is not a first-line recommendation 3.
Clinical Reality: Modest Effects at Best
The naturalistic data that does exist shows limited benefit:
- Only 57% response rate in a chart review of 42 patients, with 52% discontinuing treatment (mostly due to side effects) 4
- As adjunctive therapy to lithium, 60% showed response at 8 weeks, but this was in patients already on another mood stabilizer 5
- A Cochrane review concluded there are "insufficient trials of adequate methodological quality" to inform on efficacy and acceptability 2
Safety Concerns
Oxcarbazepine carries significant risks that must be weighed against its unproven benefit for mood swings:
- Hyponatremia (low sodium) is common and can worsen seizures or cause confusion 1
- Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly in patients with HLA-B*1502 allele (2-12% prevalence in Han Chinese populations) 1
- High rate of neuropsychiatric adverse effects: 17-39% of patients experienced these in trials versus 7-10% on placebo 2
- Suicidal ideation risk as with all antiepileptic drugs 1
The Bottom Line
Use FDA-approved mood stabilizers instead. If the patient has bipolar disorder with mood swings, start with lithium, valproate, or an atypical antipsychotic as recommended by guidelines 3. If "mood swings" refers to a different condition (borderline personality disorder, cyclothymia, etc.), oxcarbazepine still lacks evidence and should not be used.
The only potential exception would be as a last-resort adjunctive agent in treatment-refractory bipolar disorder after multiple FDA-approved options have failed, and even then, the evidence is weak 5. The research suggesting oxcarbazepine "improves mood" comes from epilepsy patients, not psychiatric populations 6, and a 2021 review concluded it has "stronger efficacy in treating acute mania than depression" but noted "a paucity of controlled acute studies" and "lack of long-term monotherapy maintenance data" 7.